Mitochondria stay healthy even under extreme stress
Deep within the cells of the kidney, a quiet metabolic catastrophe unfolds when acute injury strikes — and until now, medicine has largely watched from the outside, managing consequences rather than causes. Researchers at the University of Utah Health have identified a molecular culprit, ceramides, whose accumulation destroys the energy-producing structures inside kidney cells, and have shown in mice that blocking this process can fully reverse the injury. The discovery, published in Cell Metabolism, reframes acute kidney injury not as an inevitable collapse but as a potentially interruptible chain of events. Whether this insight will translate into human healing remains an open question, but the direction of the search has meaningfully changed.
- Acute kidney injury strikes suddenly and rarely heals on its own, leaving patients with few options beyond managing the damage already done.
- A team led by Scott Summers identified ceramide molecules as the hidden saboteurs that collapse mitochondrial function inside kidney cells, starving them of the energy needed to survive.
- Mice genetically shielded from ceramide buildup resisted kidney injury entirely, and a preclinical drug from Centaurus Therapeutics replicated that protection, keeping kidney tissue healthy even under extreme stress.
- The discovery also found ceramide levels elevated in the urine of human patients with acute kidney injury, raising the possibility of early risk detection before damage begins.
- Critical unknowns remain: the drug has never been tested in people, its safety profile is uncharted, and the mouse experiments administered it before injury — not after, as would be required in real clinical care.
- Human trials are still years away, but the research opens a door toward therapies that could also address mitochondrial dysfunction in diabetes, heart failure, and liver disease.
Your kidneys filter blood, balance salts, and regulate hormones without pause — until something like sepsis, surgery, or trauma triggers acute kidney injury. By the time symptoms appear, the damage is already deep, and kidneys rarely recover on their own. Researchers at the University of Utah Health have now published evidence that this grim pattern may not be inevitable.
In a study in Cell Metabolism, Scott Summers and his team discovered they could completely reverse acute kidney injury in mice by blocking ceramides — fat molecules that accumulate in kidney cells and destroy their mitochondria, the structures that generate cellular energy. Without that energy, kidney cells fail. When the researchers genetically prevented ceramide production, mice resisted injury even under severe conditions. A preclinical drug developed by Centaurus Therapeutics, a company Summers co-founded, produced the same effect: pre-treated mice maintained normal kidney function and showed healthy tissue under the microscope.
What distinguishes this work is its target. Rather than managing symptoms like fluid buildup or inflammation, it addresses the metabolic breakdown happening inside the cell itself. Notably, ceramide levels were also found elevated in the urine of human patients with acute kidney injury, suggesting the same mechanism may be at work in people — and potentially offering a way to identify at-risk patients before surgery or other damaging events.
Still, the distance between a mouse and a human patient is considerable. The drug is preclinical, its safety unknown, and its long-term effects unstudied. Perhaps most critically, the mice in these experiments received the drug before injury occurred — not after, as would be required in actual clinical use. Researchers must also reckon with the ways human physiology diverges from even carefully controlled laboratory animals. Human trials remain the necessary next step, and they are still years away.
Your kidneys are working right now, filtering waste from your blood, balancing the salts in your body, producing hormones that regulate everything from blood pressure to bone health. They do this work quietly, without complaint, until something goes wrong. Acute kidney injury—the sudden loss of kidney function, often triggered by sepsis, major surgery, or severe trauma—can strike without warning. By the time a patient feels sick, the damage is already substantial. And here's the cruel part: once injured, kidneys rarely recover on their own. But researchers at the University of Utah Health have just published evidence that this might not have to be true.
In a study appearing in Cell Metabolism, a team led by Scott Summers discovered that they could completely reverse acute kidney injury in mice by blocking a single type of molecule: ceramides, a form of fat that accumulates in kidney cells and destroys their mitochondria. The mitochondria are the power plants of the cell, the structures that generate the energy needed for survival. When ceramides damage them, the mitochondria lose their shape and stop working efficiently. The kidney cells, starved of energy, begin to fail. Summers and his colleagues found that when they genetically prevented ceramide production in mice, the animals did not develop kidney injury even under conditions severe enough to normally cause it. More importantly, they tested a drug candidate developed by Centaurus Therapeutics, a company Summers co-founded. Mice given this drug before injury maintained normal kidney function, stayed active, and showed healthy kidney tissue under the microscope.
What makes this work significant is not just that it reversed damage, but how it did so. Most kidney treatments target symptoms—trying to manage fluid buildup, electrolyte imbalances, or inflammation. This approach targets the root mechanism: the metabolic breakdown happening inside the cell. The researchers also found that ceramide levels spike in the urine of human patients with acute kidney injury, suggesting the same mechanism may operate in people. If that holds true, measuring urinary ceramides could become a way to identify patients at risk before they undergo surgery or experience other kidney-damaging events.
But there is a significant distance between a mouse and a human patient. The drug used in this study is preclinical—it has never been tested in people. Safety remains a major unknown. Even if blocking ceramides works in humans, researchers need to understand long-term effects, how the drug moves through the body, and what side effects might emerge. There is also the question of timing. In the mouse experiments, the drug was given before injury occurred. It is not yet clear whether the same approach would work if given after kidney damage has already started, which is how it would need to work in a real clinical setting.
If human trials do succeed, the implications could extend far beyond kidney disease. Mitochondrial dysfunction plays a role in diabetes, heart failure, and fatty liver disease. A therapy that preserves mitochondrial health might help treat multiple conditions. But the researchers themselves are cautious. The biology of mice, even carefully controlled laboratory mice, does not always predict what will happen in the messy reality of human bodies. Drug absorption differs. Immune responses differ. The way ceramides are metabolized might differ. What works in a controlled experiment can hit unexpected obstacles when it meets actual human physiology. The next step is clear: human trials. But they are still years away.
Citações Notáveis
This is the first time researchers have reversed acute kidney damage by targeting metabolism rather than symptoms— University of Utah Health research team
Results in mice don't always translate to humans. The drug used is still preclinical, and safety is a major concern— Medical experts cited in the research
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this targets metabolism rather than just treating the symptoms?
Because symptoms are what you see after the damage is done. If you're treating fluid buildup or electrolyte imbalances, you're managing the wreckage. This approach stops the wreckage from happening in the first place by keeping the cell's power plants intact.
The mice were given the drug before injury. That seems like a limitation.
It is. In real life, you can't give someone a preventive drug before they have a heart attack or sepsis—you don't know it's coming. The researchers need to figure out if the drug works when given after damage has already started, which is much harder.
What's the ceramide angle? Why is that molecule so important?
Ceramides are fats that accumulate in kidney cells under stress. They attack the mitochondria, the structures that produce energy. Once the mitochondria are damaged, the cell can't function. Block the ceramides, and the mitochondria stay healthy even under extreme stress.
Could this help other diseases?
Possibly. Mitochondrial dysfunction is involved in diabetes, heart failure, fatty liver disease. If you can preserve mitochondrial health, you might be able to treat multiple conditions. But that's speculative. Right now, the focus is on getting this to work in humans with kidney injury.
What's the biggest risk in moving from mice to humans?
Biology doesn't scale linearly. Humans have different immune systems, different drug metabolism, different body chemistry. Something that works perfectly in a controlled mouse study can fail or cause unexpected harm in people. That's why human trials take years and why safety is the real unknown here.